These studies supporting the antitumorigenic effect of PPARα agonists, combined with clinical efficacy and safety of these molecules in treating hyperlipidemia, certainly warrant closer investigation of PPARα as a therapeutic target in lung cancer. This evidence concerns the gene PPARA and lung carcinoma.